Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post Marketing Study of an in Vitro Diagnostic Test for Direct Oral Anticoagulants (Apixaban, Edoxaban, Rivaroxaban, Dabigatran) in Urine

NCT03182829 is registered in ClinicalTrials.gov with Doasense GmbH as lead sponsor.

NCT NCT03182829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03182829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post Marketing Study of an in Vitro Diagnostic Test for Direct Oral Anticoagulants (Apixaban, Edoxaban, Rivaroxaban, Dabigatran) in Urine
Lead sponsor
Doasense GmbH
Phase
Observational
Overall status
Completed
Start date
August 22, 2018
Completion date
June 5, 2019
Enrollment
880 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

anticoagulant therapy